Una mirada imageneológica, fisiopatológica y actualizada de las enfermedades huérfanas, desde la perspectiva real del departamento del Tolima
Keywords:
Mucopolysaccharides (MPS), Fabry Disease (EF), Gaucher Disease (EG), Enzyme Replacement Therapy (ERT).Abstract
During this cross-sectional retrospective descriptive review, the aim is to establish from
the prevalence of these pathologies to the main sociodemographic factors, the main
clinical and radiological characteristics, and to establish the main associations between
the diseases and the sociodemographic, clinical, radiological and survival factors in
patients. reported to SIVIGILA in the department of Tolima between the years 2017 - 2018.
Orphan diseases occur in a small part of the population but are chronically devastating,
fatal and debilitating in the short term, with multiple etiologies, one of the main ones
being genetic changes and inheritance among relatives; Being illnesses of low prevalence
in the population, the studies and information on it is limited, so it was decided to form
a descriptive study on the sociodemographic, clinical and radiological characterizationof the patients in the department of Tolima, registered within the platform of SIVIGILA
epidemiological surveillance in 2017 and 2018.
In the department of Tolima there is no information about lysosomal storage diseases
such as Mucopolysaccharidosis and Fabry disease and taking into account the above
about being a group of diseases that generate a high cost to the health system, calculating
on average a total of 480,173 euros per year, with regard to enzyme replacement therapy
(3), apart from the expenses provided by multiple admissions to intensive care units,
hospitalizations and interdisciplinary management and also because it is a chronic
disease that has no cure, leads the family of the person who suffers to generate other
types of extra expenses such as travel to controls and care at home, in most cases the
needs and dependence of those affected forces them to there is a constant caregiver,
who is often the mother or father, providing a decrease in income in the family. Currently,
the department has only one case presentation regarding Gaucher disease.
According to the above, the need arises to study and document the characterization of
this type of pathologies in the department of Tolima, to know their behavior and answer,
What is the prevalence of Mucopolysaccharidosis, Fabry’s disease, Gaucher’s disease;
the main sociodemographic, clinical and radiological factors; in addition to the main
associations between diseases and sociodemographic, clinical and radiological factors,
and survival, in patients reported to SIVIGILA in the department of Tolima between the
years 2017 - 2018 .
References
Suarez Guerrero L, Gómez Higuera PJI, Arias Flórez S, Contreras García A. Mucopolisacaridosis: características clínicas, diagnóstico y de manejo. Revista Chilena de Pediatría. 2015;87(4).
García Díaz JD, Mesa Latorre, Corps Fernández, Valbuena Parra. Enfermedades por depósito lisosomal. Medicine. 2016;19(12).
Expósito JÁ, Paladio N. Tratamiento de sustitución enzimática en enfermedades por depósito lisosomal: revisión sistemática e impacto presupuestario. Informes de Evaluación de Tecnologías Sanitarias. Barcelona: Ministerio de Sanidad, Consumo y Bienestar Social; 2018.
Alméciga-Diaz CJ, Barrera LA. Design and applications of gene therapy vectors for mucopolysaccharidosis in Colombia. Springer Nature. 2019.
Germain DP, Hughes DA, Nicholls K, Bichet DG. Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat. The New England Journal of Medicine. 201;376(6).
Lin HY, Chuang CK, Huang YH, Tu RY, Lin FJ, Lin SJ, et al. Causes of death and clinical characteristics of 34 patients with Mucopolysaccharidosis II in Taiwan from 1995–2012. BioMed Central, Lin et al. Orphanet Journal of Rare Diseases. 2016;11(85).
Riera MdT, Sanjurjo P, Dalmau Serra, Miñana I, Guillén Navarro E, Pérez J, et al. Guía para el manejo de las Mucopolisacaridosis. 1st ed. 978-84-16270-04-0 I. Majadahonda (Madrid): Ergon; 2015.
Guillén Navarro E, Blasco AJ, Gutierrez Solana LG, Couce ML, Cancho Candela , Lázaro P. Guía de práctica cıínica para el tratamiento del síndrome de Hunter. Medicina Clínica. 2013;141(10).
Silva Lopes, Serra Filho DP, Almeida Matos M. Functional independence of pediatric patients with mucopolysaccharidoses. Acta Ortop Bras. 2019;27(4).
Barba Romero M, Serena J, Puig JM, Valverde C, Climent V, Herrero, et al. Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy. Medicina Clínica. 2019;153(2).
El Abassi R, Singhal, England JD. Fabry’s disease. Journal of the Neurological Sciences. 2014;344.
Di Toro, Favalli, Arbustini. Anderson–Fabry disease. Journal of Cardiovascular Medicine. 2018 February; 19(1).
Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of Lysosomal Storage Disorders. JAMA. 1999;281(3):249-254.
Cantillo JdJ, Rojas W. Enfermedad de Fabry: Descripción de un caso y su evolución en terapia de reemplazo enzimático. Acta Médica Colombiana. 2014;39(2).
Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Tei, C. Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney International. 2003;64(3):801-807.
Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology-Oxford University. 2011;50:v4-12.
Suárez Obando F, Zarante Montoya I. Aspectos clínicos y manejo integral del síndrome de Morquio. Universitas Médica. 2007;48(2):166-174.
Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin SP, Parini R. The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Molecular Genetics and Metabolism. 2013;109(1):54-61.
Lozano Bernal E. Enfermedad de Gaucher: Casuística del Tolima. Acta médica colombiana. 2006;31(4):416-421.
Rua Elorduy M. Enfermedades Metabólicas Lisosomales. Manifetaciones Osteoarticulares. Protoc diagn ter pediatr. 2014;1:231-239.
Gómez AM, García Robles R, Suárez Obando F. Estimación de las frecuencias de las mucopolisacaridosis y análisis de agrupamiento espacial en los departamentos de Cundinamarca y Boyacá. Biomédica. 2012;32(4):602-609.
Kato Z, Fukuda S, Tomatsu S, Vega H, Yasunaga T, Yamagishi A, Orii, T. A novel common missense mutation G301C in the N-acetylgalactosamine-6-sulfate sulfatase gene in mucopolysaccharidosis IVA. Human Genetics.1997;101(1):97-101.
Montaño AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A Registry: Clinical manifestation and natural course of Morquio A disease. Journal of Inherited Metabolic Disease. 2007;30(2):165-174.
Meikle PJ, Hopwood JJ. Lysosomal storage disorders: emerging therapeutic options require early diagnosis. European Journal of Pediatrics. 2003;162(1):S34–S37.
Harmatz P. Enzyme Replacement Therapies and Immunogenicity in Lysosomal Storage Diseases: Is Therea Pattern? Clinical Therapeutics. 2015;37(9):2130-2134.
Ballabio A, Gieselmann, B. Lysosomal disorders: From storage to cellular damage. Biochimica et Biophysica Acta. 2009;1793(4):684–696.
Cozma C, Eichler S, Wittmann G, Flores Bonet A, Kramp GJ, Giese AK, Rolfs A. Diagnosis of Morquio Syndrome in Dried Blood Spots Based on a New MRM-MS Assay. PLOS ONE. 2015;10(7):1-14.
Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology. 2011;50(SUPPL 5).
Jackson M, Roberts A, Martin E, Rout Pitt N, Gronthos S, Byers S. Mucopolysaccharidosis enzyme production by bone marrow and dental pulp derived human mesenchymal stem cells. Molecular Genetics and Metabolism. 2015;114(4):584-593.
Rowan DJ, Tomatsu S, Grubb JH, Montaño AM, Sly WS. Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII. Journal of Inherited Metabolic Disease. 2013;36(2):235–246.
Higuchi T, Shimizu H, Fukuda T, Kawagoe S, Matsumoto J, Shimada Y, Hirato, T. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II. Molecular Genetics and Metabolism. 2012;107(1-2):122-128.
Morrone A, Caciotti A, Atwood R, Davidson K, Du C, Francis Lyon P, Ryles A. Morquio A Syndrome-Associated Mutations: A Review of Alterations in the GALNS Gene and a New Locus-Specific Database. Human Mutation. 2014;35(11):1271–1279.
Camelier MV, Burin MG, De Mari J, Vieira TA, Marasca G, Giugliani R. Practical and reliable enzyme test for the detection of Mucopolysaccharidosis IVA (Morquio Syndrome type A) in dried blood samples. Clinica Chimica Acta. 2011;412(19-20):1805–1808.
Dũng VC, Tomatsu S, Montaño AM, Gottesman G, Bober MB, Mackenzie W, Orii T. Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels. Molecular Genetics and Metabolism. 2013;110(0): p.129–138.
Negretto GW, Deon M, Burin M, Biancini GB, Ribas G, Garcia SC, Vargas CR. In vitro effect of genistein on DNA damage in leukocytes from mucopolysaccharidosis IVA patients. Molecular Genetics and Metabolism. 2014;111(2):205-208.
Clarke LA, Winchester B, Giugliani R, Tylki Szymańska A, Amartino H. Biomarkers for the mucopolysaccharidoses: Discovery and clinical utility. Molecular Genetics and Metabolism. 2012 ;106(4):395-402.
Burrow A, Leslie N. Review of the use of idursulfase in the treatment of mucopolysaccharidosis II. Biologics. 2008; 2(2):311-320.
Aerts JM, Kallemeijn WW, Wegdam W, Joao Ferraz M, Van Breemen MJ, Dekke N, Rombach, S. M. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. 2011;34:
-619.
Burton BK. Inborn Errors of Metabolism in Infancy: A Guide to Diagnosis. Pediatrics. 1998;102(E69):1-9.
Oussoren E. Brands MMM,G. Ruijter GJG, Van der Ploeg AT, Reuser AJJ. Bone, joint and tooth development in mucopolysaccharidoses: Relevance to therapeutic options. Biochimica et Biophysica Acta. 2011;1812.
Downloads
Published
Versions
- 2025-11-11 (3)
- 2025-11-11 (2)
- 2021-04-15 (1)
How to Cite
Issue
Section
License
Copyright (c) 2021 Scientific and Eduaction Medical Journal

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Atribución – No comercial – Compartir igual: Esta licencia permite a otros distribuir, remezclar, retocar, y crear a partir de tu obra de modo no comercial, siempre y cuando te den crédito y licencien sus nuevas creaciones bajo las mismas condiciones.
Attribution-NonCommercial-ShareAlike 4.0 International


